BOL-148

BOL-148
Clinical data
Other names	BOL148; BOL; 2-Bromo-LSD; 2-Br-LSD; 2-bromolysergic acid diethylamide; Bromolysergide; Bromine-LSD; BETR-001; BTR001; TD-0148A; TD0148A; NYPRG-101; NYPRG101; 2-Bromo-N,N-diethyllysergamide; 2-Bromo-N,N-diethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Routes of; administration	Oral
Drug class	Serotonin receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Legal status
Legal status	Not scheduled (United States, Canada, Germany, EU precursors);
Identifiers
	IUPAC name (6aR,9R)-5-bromo-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	478-84-2 ;
PubChem CID	10171;
IUPHAR/BPS	272;
ChemSpider	9765 ;
UNII	JUA77QEU32;
ChEMBL	ChEMBL274384 ;
PDB ligand	A1AFU (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30878496 ;
Chemical and physical data
Formula	C20H24BrN3O
Molar mass	402.336 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C;
	InChI InChI=1S/C20H24BrN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1 ; Key:VKRAXSZEDRWLAG-SJKOYZFVSA-N ;
	(verify)

BOL-148, also known as 2-bromo-LSD or as bromolysergide, is a non-hallucinogenic serotonin receptor modulator of the lysergamide family related to the psychedelic drug lysergic acid diethylamide (LSD). It is specifically the 2-bromo derivative of LSD.

The drug is a non- or minimally-hallucinogenic serotonin 5-HT_2A receptor partial agonist, as well as acting at other targets such as other serotonin receptors and dopamine receptors. The lack of psychedelic effects with BOL-148 is thought to be due to lower-efficacy partial agonism at the serotonin 5-HT_2A receptor compared to LSD that is insufficient to produce hallucinogenic effects. The drug has been found to produce psychoplastogenic and antidepressant-like effects in animals.

BOL-148 was initially developed by Albert Hofmann in the 1950s, as part of the original research from which LSD was also derived. It is now being reinvestigated and is under development for the potential treatment of cluster headaches and other conditions. This is under new developmental code names including BETR-001, TD-0148A, and NYPRG-101.